FERRANTE DOMENIC J 4
4 · Finch Therapeutics Group, Inc. · Filed Mar 25, 2021
Insider Transaction Report
Form 4
FERRANTE DOMENIC J
Director
Transactions
- Conversion
Series D Preferred Stock
2021-03-23−90,378→ 0 total(indirect: See footnote)→ Common Stock (90,378 underlying) - Conversion
Series C Preferred Stock
2021-03-23−300,948→ 0 total(indirect: See footnote)→ Common Stock (300,948 underlying) - Conversion
Common Stock
2021-03-23+90,378→ 533,254 total(indirect: See footnote) - Conversion
Series B Preferred Stock
2021-03-23−141,928→ 0 total(indirect: See footnote)→ Common Stock (141,928 underlying) - Conversion
Common Stock
2021-03-23+141,928→ 141,928 total(indirect: See footnote) - Purchase
Common Stock
2021-03-23$17.00/sh+102,941$1,749,997→ 636,195 total(indirect: See footnote) - Conversion
Common Stock
2021-03-23+300,948→ 442,876 total(indirect: See footnote)
Footnotes (2)
- [F1]Each share of Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date.
- [F2]The securities are held by The Domenic J. Ferrante 2006 Investment Trust (the "Trust"). The Reporting Person is the trustee of the Trust.